Working… Menu

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00101972
Recruitment Status : Completed
First Posted : January 19, 2005
Last Update Posted : April 20, 2012
Information provided by (Responsible Party):

Brief Summary:

RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.

Condition or disease Intervention/treatment Phase
Cancer Biological: monoclonal antibody RAV12 Phase 1

Detailed Description:


  • Determine the maximum tolerated dose of RAV12 in patients with metastatic or recurrent adenocarcinoma.
  • Determine the toxicity profile of this drug in these patients.
  • Determine the pharmacokinetics and immunogenicity of this drug in these patients.
  • Determine, preliminarily, the antitumor activity of this drug in these patients.

OUTLINE: This is an open-label, dose-escalation study.

Patients receive RAV12 IV over 2 hours 2-3 times per week in weeks 1-4 (course 1). Patients are evaluated for response on day 43. Patients achieving a partial or complete response may be eligible to receive additional courses of RAV12 as above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of RAV12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Up to 15 additional patients are treated at the MTD in 1 or more patients groups (e.g., colorectal, pancreatic, gastroesophageal, and other adenocarcinoma).

After completion of study treatment, patients are followed within 4 weeks and then every 6-12 months thereafter.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma
Study Start Date : December 2004
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Arm Intervention/treatment
Experimental: RAV12 Biological: monoclonal antibody RAV12
Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks

Primary Outcome Measures :
  1. Toxicity by CTCAE [ Time Frame: Days 1-50 ]

Secondary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: Days 1-50 ]
  2. Pharmacokinetics of RAV12 by serum levels [ Time Frame: Days 1, 2, 4, 5, 8, 15, 22, 29, 36, 43, and 50 ]
  3. Immunogenicity by Human Anti-chimeric antibodies [ Time Frame: Days 1, 8, 15, 22, and 50 ]
  4. Time to tumor progression by clinical assessment [ Time Frame: 6 months ]
  5. Progression free survival by clinical assessment [ Time Frame: 3 and 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma

    • Metastatic or recurrent disease
    • Not curable by standard therapies
  • Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease

    • Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies
    • Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression
  • Meets 1 of the following criteria:

    • At least 1 measurable site of disease ≥ 2 cm by radiography
    • Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator
  • RAAG12 expression confirmed* by immunohistochemistry NOTE: *Not required for patients with colon, pancreatic, or gastric adenocarcinoma
  • No evidence of residual or recurrent CNS metastases
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Not specified

Menopausal status

  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • More than 3 months


  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
  • Absolute neutrophil count ≥ 1,500/mm^3


  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • γ-glutamyl transferase ≤ 2.5 times ULN
  • Adequate hepatic function sufficient to undergo study therapy


  • Creatinine < 1.5 mg/dL
  • Adequate renal function sufficient to undergo study therapy


  • No New York Heart Association class III or IV heart disease
  • No thrombosis within the past 3 months, including any of the following:

    • Deep vein thrombosis
    • Myocardial infarction
    • Stroke
  • Adequate cardiac function sufficient to undergo study therapy


  • No pulmonary embolism within the past 3 months
  • No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis
  • Adequate pulmonary function sufficient to undergo study therapy


  • No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks
  • No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents
  • No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug


  • Amylase and lipase normal
  • No other primary malignancy within the past 3 years except for the following:

    • Treated non-melanoma skin cancer
    • Carcinoma in situ of the cervix by biopsy
    • Squamous intraepithelial lesion of the cervix by PAP smear
    • Localized prostate cancer (Gleason score < 6)
    • Resected melanoma in situ
  • No other serious medical condition that would preclude study participation
  • No dementia or altered mental status that would preclude giving informed consent
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation


Biologic therapy

  • At least 3 half-lives since prior monoclonal antibody therapy
  • No concurrent vaccinations
  • No concurrent prophylactic hematologic growth factors


  • At least 4 weeks since prior chemotherapy

Endocrine therapy

  • No concurrent steroids except for the following:

    • Inhaled, ophthalmic, or nasal steroids
    • Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day


  • At least 4 weeks since prior radiotherapy


  • More than 4 weeks since prior major surgery


  • More than 4 weeks since prior investigational agents
  • Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week
  • No other concurrent antineoplastic therapy
  • No concurrent immunosuppressive medications
  • No other concurrent investigational agents
  • No concurrent vitamins except those approved by the medical monitor

    • Concurrent daily multivitamin allowed
  • Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00101972

Layout table for location information
United States, California
Premiere Oncology
Santa Monica, California, United States, 90404
United States, District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Florida
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States, 33136
United States, Pennsylvania
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States, 19111-2497
United States, Tennessee
Sarah Cannon Cancer Center at Centennial Medical Center
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Layout table for investigator information
Study Director: Stanford J Stewart, MD MacroGenics
Publications of Results:
Layout table for additonal information
Responsible Party: MacroGenics Identifier: NCT00101972    
Other Study ID Numbers: CDR0000415581
RAVENBIO-RV-2004-002 ( Other Identifier: Raven biotechnologies (MacroGenics) )
First Posted: January 19, 2005    Key Record Dates
Last Update Posted: April 20, 2012
Last Verified: April 2012
Keywords provided by MacroGenics:
adenocarcinoma of the bladder
adenocarcinoma of the colon
adenocarcinoma of the esophagus
adenocarcinoma of the extrahepatic bile duct
adenocarcinoma of the gallbladder
adenocarcinoma of the lung
adenocarcinoma of the pancreas
adenocarcinoma of the prostate
adenocarcinoma of the rectum
adenocarcinoma of the stomach
adenocarcinoma with squamous metaplasia of the gallbladder
cervical adenocarcinoma
endometrial adenocarcinoma
ovarian endometrioid adenocarcinoma
ovarian undifferentiated adenocarcinoma
salivary gland adenocarcinoma
small intestine adenocarcinoma
vaginal adenocarcinoma
vaginal clear cell adenocarcinoma
ovarian clear cell cystadenocarcinoma
ovarian mucinous cystadenocarcinoma
ovarian serous cystadenocarcinoma
stage IV bladder cancer
stage IV breast cancer
stage IV colon cancer
stage IV endometrial carcinoma
stage IV esophageal cancer
stage IV gastric cancer
stage IV non-small cell lung cancer
stage IV ovarian epithelial cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs